Pre-operative Intranasal Oxytocin for Enhancing Bariatric-induced Diabetes Remission
Status:
Active, not recruiting
Trial end date:
2025-08-30
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind, placebo-controlled study of the effects of intranasal
oxytocin in obese adults with diabetes undergoing bariatric surgery. Subjects will be
randomized to receive of intranasal oxytocin or placebo (8 units 3 times daily) for 8 weeks
prior surgery. Study visits include screening to determine eligibility, CGM will be connected
before and after oxytocin administration, and 1 year post surgery. blood tests including oral
glucose tolerance test will be done and fat samples will be taken during surgery. The
investigator's hypothesis is that oxytocin administration prior bariatric surgery can induce
diabetes remission in patients with diabetes